13 results on '"Battilomo S"'
Search Results
2. [The health determinants in young children: testing a new surveillance system in Italy]
- Author
-
Pizzi, E., Spinelli, A., Battilomo, S., Azzarito, C., Balducci, M. T., Bettinelli, M. E., Campostrini, S., Germinario, C., Mazzarella, Guido, Mignuoli, A. D., Morbidoni, M., Porchia, Stefania, Simeoni, Loris, Speri, Laura, Bucciarelli, M., Buoncristiano, M., Lauria, L., Nardone, P., Privitera, M. G., Brancati, G., Raffa, R., Napoli, T., Cimminelli, L., Vitelli, A., Panico, M., Ragone, G., D'Anna, A., Nardacci, A., Benedetti, E., Ambrogiani, E., Guidi, A., Cimini, D., Marcolini, P., Pasqualini, F., Rossini, Roberta, Zappi, W., Lacaita, G., Valentini, M., Pedote, P. D., Pesare, A., Caputi, G., Gottardello, L., and Campi, Davide
- Subjects
Vaccination centres ,Childhood ,Health determinants ,Surveillance system ,Italy ,Child, Preschool ,Population Surveillance ,Child Health ,Humans ,Infant ,Settore SECS-S/05 - Statistica Sociale - Abstract
In recent years, the scientific community has stressed the need to invest in the first 1,000 days of life - the time spanning between conception and the 2nd birthday - because it is during this period that the foundations of health are laid and whose effects will be present throughout the life and may influence the next generation. Taking this into account, in 2013 the National Centre for Disease Prevention and Control (CCM) of the Italian Ministry of Health promoted and financed a project to test a surveillance system of the main determinants of health concerning the child between the conception period and the 2nd years of life which are included in the National Programme "GenitoriPiù": folic acid before and during pregnancy, abstention from tobacco and alcohol during pregnancy and lactation, breastfeeding, infant sleep position, vaccination attitude, and early reading. The Project, started in January 2014 and ended in August 2016, has piloted the design, testing, and evaluation of the surveillance system with the view to national extension and the repeatability over time. The surveillance system has been designed to collect data through a questionnaire compiled by mothers in vaccination centres, in order to produce indicators which will enable territorial and intertemporal comparisons to be made. The project has shown the feasibility of this system, identifying favourable conditions and possible difficulties, and its ability to collect important information on children's health.
- Published
- 2019
3. Consensus paper on postural dysfunction: Recommendations for prevention, diagnosis and therapy
- Author
-
R, Saggini, G P, Anastasi, S, Battilomo, P, Maietta Latessa, G, Costanzo, F, Di Carlo, F, Festa, G, Giardinelli, F, Macrì, L, Mastropasqua, M, Nardone, G, Nicoletti, A, Orsini, M, Pastorelli, R, Pellegrino, M, Trevisan, L, La Mesa, A M, Le Pera, M G, Privitera, G, Ralli, C, Villani, B, Bricot, R G, Davidson, A, Hassdenteufel, Z M, Hawamdeh, G J, Kleinrensink, E, Matheron, V L, Stoev, S, Stratulat, S, Tiron, P, Villeneuve, T, Paolucci, R G, Bellomo, Saggini R., Anastasi G.P., Battilomo S., Maietta Latessa P., Costanzo G., Di Carlo F., Festa F., Giardinelli G., Macri F., Mastropasqua L., Nardone M., Nicoletti G., Orsini A., Pastorelli M., Pellegrino R., Trevisan M., La Mesa L., Le Pera A.M., Privitera M.G., Ralli G., Villani C., Bricot B., Davidson R.G., Hassdenteufel A., Hawamdeh Z.M., Kleinrensink G.J., Matheron E., Stoev V.L., Stratulat S., Tiron S., Villeneuve P., Paolucci T., Bellomo R.G., and Neurosciences
- Subjects
Balance ,scoliosis ,Consensus ,Foot ,Posture ,Rehabilitation ,Consensu ,Elderly ,SDG 3 - Good Health and Well-being ,balance ,child, elderly ,exercise ,foot ,posture ,rehabilitation ,Scoliosi ,Child ,Exercise ,Postural Balance - Abstract
Good fundamentals of posture and balance are essential for the efficient performance of both simple daily tasks and more complex movement patterns. In particular, postural balance is the ability to keep the body in equilibrium and to regain balance after the shift of body segments: postural control mechanisms of integration of the visual, vestibular and foot afferential channels contribute to this. This document provides recommendations based on scientific evidence, clinical practice, and consensus between experts concerning the prevention, diagnosis, and treatment of postural dysfunction at the three stages of life as the developmental age, adult age, and old age > 65 years and follows the “National Guidelines on Classification and Measuring of Posture and its Dysfunctions” per the Italian Ministry of Health (December 2017). The paper answers four main questions: i) “Which measures can be adopted to prevent postural dysfunctions?" ii) “What can we do in order to make a correct diagnosis of postural dysfunction?" iii) “What are the correct treatment programs for postural dysfunctions?" iv) Which professional competencies and experiences are useful for preventing, diagnosing and treating postural dysfunctions? By the Consensus of the Experts and the scientific evidence, emerge that the approach to postural dysfunctions requires a multidisciplinary and interdisciplinary team. Furthermore, rehabilitation treatment interventions must be specific to the age groups that have been indicated, to consider the integration of the main systems and subsystems of postural control that change with age.
- Published
- 2021
4. Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023.
- Author
-
Fabiani M, Mateo-Urdiales A, Sacco C, Fotakis EA, Battilomo S, Petrone D, Del Manso M, Bella A, Riccardo F, Stefanelli P, Palamara AT, and Pezzotti P
- Subjects
- Humans, Aged, Male, Italy epidemiology, Female, Retrospective Studies, Middle Aged, Aged, 80 and over, Seasons, mRNA Vaccines, Hospitalization statistics & numerical data, COVID-19 prevention & control, COVID-19 epidemiology, Immunization, Secondary, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, SARS-CoV-2 immunology, SARS-CoV-2 genetics, Vaccine Efficacy
- Abstract
Evaluating how a COVID-19 seasonal vaccination program performed might help to plan future campaigns. This study aims to estimate the relative effectiveness (rVE) against severe COVID-19 of a seasonal booster dose over calendar time and by time since administration. We conducted a retrospective cohort analysis among 13,083,855 persons aged ≥60 years who were eligible to receive a seasonal booster at the start of the 2022-2023 vaccination campaign in Italy. We estimated rVE against severe COVID-19 (hospitalization or death) of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines by two-month calendar interval and at different times post-administration. We used multivariable Cox regression models, including vaccination as time-dependent exposure, to estimate adjusted hazard ratios (HR) and rVEs as [(1-HR)X100]. The rVE of a seasonal booster decreased from 64.9% (95% CI: 59.8-69.4) in October-November 2022 to 22.0% (95% CI: 15.4-28.0) in April-May 2023, when the majority of vaccinated persons (67%) had received the booster at least 4-6 months earlier. During the epidemic phase with prevalent circulation of the Omicron BA.5 subvariant, rVE of a seasonal booster received ≤90 days earlier was 83.0% (95% CI: 79.1-86.1), compared to 37.4% (95% CI: 25.5-47.5) during prevalent circulation of the Omicron XBB subvariant. During the XBB epidemic phase, rVE was estimated at 15.8% (95% CI: 9.1-20.1) 181-369 days post-administration of the booster dose. In all the analyses we observed similar trends of rVE between persons aged 60-79 and those ≥80 years, although estimates were somewhat lower for the oldest group. A seasonal booster dose received during the vaccination campaign provided additional protection against severe COVID-19 up to April-May 2023, after which the incidence of severe COVID-19 was much reduced. The results also suggest that the Omicron XBB subvariant might have partly escaped the immunity provided by the seasonal booster targeting the original and Omicron BA.4-5 strains of SARS-CoV-2., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. A new digital model for the Italian Integrated Home Care: strengths, barriers, and future implications.
- Author
-
Cascini F, Gentili A, Melnyk A, Beccia F, Causio FA, Solimene V, Battilomo S, Paone S, Borghini A, Bartolo M, Chiarolla E, and Ricciardi W
- Subjects
- Humans, Forecasting, Italy, Home Care Services, Telemedicine
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
6. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
- Author
-
Fabiani M, Mateo-Urdiales A, Sacco C, Rota MC, Petrone D, Bressi M, Del Manso M, Siddu A, Proietti V, Battilomo S, Menniti-Ippolito F, Popoli P, Bella A, Riccardo F, Palamara AT, Rezza G, Brusaferro S, and Pezzotti P
- Subjects
- Aged, Humans, Cohort Studies, Retrospective Studies, SARS-CoV-2, Italy epidemiology, mRNA Vaccines, COVID-19 Vaccines, COVID-19 prevention & control
- Abstract
Several countries started a 2nd booster COVID-19 vaccination campaign targeting the elderly population, but evidence around its effectiveness is still scarce. This study aims to estimate the relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine in the population aged ≥ 80 years in Italy, during predominant circulation of the Omicron BA.2 and BA.5 subvariants. We linked routine data from the national vaccination registry and the COVID-19 surveillance system. On each day between 11 April and 6 August 2022, we matched 1:1, according to several demographic and clinical characteristics, individuals who received the 2nd booster vaccine dose with individuals who received the 1st booster vaccine dose at least 120 days earlier. We used the Kaplan-Meier method to compare the risks of SARS-CoV-2 infection and severe COVID-19 (hospitalisation or death) between the two groups, calculating the relative vaccine effectiveness (RVE) as (1 - risk ratio)X100. Based on the analysis of 831,555 matched pairs, we found that a 2nd booster dose of mRNA vaccine, 14-118 days post administration, was moderately effective in preventing SARS-CoV-2 infection compared to a 1st booster dose administered at least 120 days earlier [14.3 %, 95 % confidence interval (CI): 2.2-20.2]. RVE decreased from 28.5 % (95 % CI: 24.7-32.1) in the time-interval 14-28 days to 7.6 % (95 % CI: -14.1 to 18.3) in the time-interval 56-118 days. However, RVE against severe COVID-19 was higher (34.0 %, 95 % CI: 23.4-42.7), decreasing from 43.2 % (95 % CI: 30.6-54.9) to 27.2 % (95 % CI: 8.3-42.9) over the same time span. Although RVE against SARS-CoV-2 infection was much reduced 2-4 months after a 2nd booster dose, RVE against severe COVID-19 was about 30 %, even during prevalent circulation of the Omicron BA.5 subvariant. The cost-benefit of a 3rd booster dose for the elderly people who received the 2nd booster dose at least four months earlier should be carefully evaluated., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
- Author
-
Sacco C, Del Manso M, Mateo-Urdiales A, Rota MC, Petrone D, Riccardo F, Bella A, Siddu A, Battilomo S, Proietti V, Popoli P, Menniti Ippolito F, Palamara AT, Brusaferro S, Rezza G, Pezzotti P, and Fabiani M
- Subjects
- BNT162 Vaccine, COVID-19 Vaccines, Child, Humans, Retrospective Studies, SARS-CoV-2, COVID-19 epidemiology, COVID-19 prevention & control, Viral Vaccines
- Abstract
Background: By April 13, 2022, more than 4 months after the approval of BNT162b2 (Pfizer-BioNTech) for children, less than 40% of 5-11-year-olds in Italy had been vaccinated against COVID-19. Estimating how effective vaccination is in 5-11-year-olds in the current epidemiological context dominated by the omicron variant (B.1.1.529) is important to inform public health bodies in defining vaccination policies and strategies., Methods: In this retrospective population analysis, we assessed vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19, defined as an infection leading to hospitalisation or death, by linking the national COVID-19 surveillance system and the national vaccination registry. All Italian children aged 5-11 years without a previous diagnosis of infection were eligible for inclusion and were followed up from Jan 17 to April 13, 2022. All children with inconsistent vaccination data, diagnosed with SARS-CoV-2 infection before the start date of the study or without information on the municipality of residence were excluded from the analysis. With unvaccinated children as the reference group, we estimated vaccine effectiveness in those who were partly vaccinated (one dose) and those who were fully vaccinated (two doses)., Findings: By April 13, 2022, 1 063 035 (35·8%) of the 2 965 918 children aged 5-11 years included in the study had received two doses of the vaccine, 134 386 (4·5%) children had received one dose only, and 1 768 497 (59·6%) were unvaccinated. During the study period, 766 756 cases of SARS-CoV-2 infection and 644 cases of severe COVID-19 (627 hospitalisations, 15 admissions to intensive care units, and two deaths) were notified. Overall, vaccine effectiveness in the fully vaccinated group was 29·4% (95% CI 28·5-30·2) against SARS-CoV-2 infection and 41·1% (22·2-55·4) against severe COVID-19, whereas vaccine effectiveness in the partly vaccinated group was 27·4% (26·4-28·4) against SARS-CoV-2 infection and 38·1% (20·9-51·5) against severe COVID-19. Vaccine effectiveness against infection peaked at 38·7% (37·7-39·7) at 0-14 days after full vaccination and decreased to 21·2% (19·7-22·7) at 43-84 days after full vaccination., Interpretation: Vaccination against COVID-19 in children aged 5-11 years in Italy showed a lower effectiveness in preventing SARS-CoV-2 infection and severe COVID-19 than in individuals aged 12 years and older. Effectiveness against infection appears to decrease after completion of the current primary vaccination cycle., Funding: None., Translation: For the Italian translation of the summary see Supplementary Materials section., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
8. Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021.
- Author
-
Fabiani M, Puopolo M, Filia A, Sacco C, Mateo-Urdiales A, Spila Alegiani S, Del Manso M, D'Ancona F, Vescio F, Bressi M, Petrone D, Spuri M, Rota MC, Massari M, Da Cas R, Morciano C, Stefanelli P, Bella A, Tallon M, Proietti V, Siddu A, Battilomo S, Palamara AT, Popoli P, Brusaferro S, Rezza G, Riccardo F, Menniti Ippolito F, and Pezzotti P
- Subjects
- Humans, SARS-CoV-2, Vaccines, Synthetic, mRNA Vaccines, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
Background: Consolidated information on the effectiveness of COVID-19 booster vaccination in Europe are scarce., Research Design and Methods: We assessed the effectiveness of a booster dose of an mRNA vaccine against any SARS-CoV-2 infection (symptomatic or asymptomatic) and severe COVID-19 (hospitalization or death) after over two months from administration among priority target groups (n = 18,524,568) during predominant circulation of the Delta variant in Italy (July-December 2021)., Results: Vaccine effectiveness (VE) against SARS-CoV-2 infection and, to a lesser extent, against severe COVID-19, among people ≥60 years and other high-risk groups (i.e. healthcare workers, residents in long-term-care facilities, and persons with comorbidities or immunocompromised), peaked in the time-interval 3-13 weeks (VE against infection = 67.2%, 95% confidence interval (CI): 62.5-71.3; VE against severe disease = 89.5%, 95% CI: 86.1-92.0) and then declined, waning 26 weeks after full primary vaccination (VE against infection = 12.2%, 95% CI: -4.7-26.4; VE against severe disease = 65.3%, 95% CI: 50.3-75.8). After 3-10 weeks from the administration of a booster dose, VE against infection and severe disease increased to 76.1% (95% CI: 70.4-80.7) and 93.0% (95% CI: 90.2-95.0), respectively., Conclusions: These results support the ongoing vaccination campaign in Italy, where the administration of a booster dose four months after completion of primary vaccination is recommended.
- Published
- 2022
- Full Text
- View/download PDF
9. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
- Author
-
Fabiani M, Puopolo M, Morciano C, Spuri M, Spila Alegiani S, Filia A, D'Ancona F, Del Manso M, Riccardo F, Tallon M, Proietti V, Sacco C, Massari M, Da Cas R, Mateo-Urdiales A, Siddu A, Battilomo S, Bella A, Palamara AT, Popoli P, Brusaferro S, Rezza G, Menniti Ippolito F, and Pezzotti P
- Subjects
- 2019-nCoV Vaccine mRNA-1273 administration & dosage, Adolescent, Adult, Aged, Aged, 80 and over, BNT162 Vaccine administration & dosage, COVID-19 diagnosis, COVID-19 immunology, COVID-19 prevention & control, Female, Follow-Up Studies, Humans, Immunogenicity, Vaccine, Incidence, Italy epidemiology, Male, Middle Aged, SARS-CoV-2 isolation & purification, Severity of Illness Index, Time Factors, Treatment Outcome, Vaccination statistics & numerical data, Young Adult, 2019-nCoV Vaccine mRNA-1273 immunology, BNT162 Vaccine immunology, COVID-19 epidemiology, Immunization, Secondary statistics & numerical data, SARS-CoV-2 pathogenicity
- Abstract
Objectives: To estimate the effectiveness of mRNA vaccines against SARS-CoV-2 infection and severe covid-19 at different time after vaccination., Design: Retrospective cohort study., Setting: Italy, 27 December 2020 to 7 November 2021., Participants: 33 250 344 people aged ≥16 years who received a first dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine and did not have a previous diagnosis of SARS-CoV-2 infection., Main Outcome Measures: SARS-CoV-2 infection and severe covid-19 (admission to hospital or death). Data were divided by weekly time intervals after vaccination. Incidence rate ratios at different time intervals were estimated by multilevel negative binomial models with robust variance estimator. Sex, age group, brand of vaccine, priority risk category, and regional weekly incidence in the general population were included as covariates. Geographic region was included as a random effect. Adjusted vaccine effectiveness was calculated as (1-IRR)×100, where IRR=incidence rate ratio, with the time interval 0-14 days after the first dose of vaccine as the reference., Results: During the epidemic phase when the delta variant was the predominant strain of the SARS-CoV-2 virus, vaccine effectiveness against SARS-CoV-2 infection significantly decreased (P<0.001) from 82% (95% confidence interval 80% to 84%) at 3-4 weeks after the second dose of vaccine to 33% (27% to 39%) at 27-30 weeks after the second dose. In the same time intervals, vaccine effectiveness against severe covid-19 also decreased (P<0.001), although to a lesser extent, from 96% (95% to 97%) to 80% (76% to 83%). High risk people (vaccine effectiveness -6%, -28% to 12%), those aged ≥80 years (11%, -15% to 31%), and those aged 60-79 years (2%, -11% to 14%) did not seem to be protected against infection at 27-30 weeks after the second dose of vaccine., Conclusions: The results support the vaccination campaigns targeting high risk people, those aged ≥60 years, and healthcare workers to receive a booster dose of vaccine six months after the primary vaccination cycle. The results also suggest that timing the booster dose earlier than six months after the primary vaccination cycle and extending the offer of the booster dose to the wider eligible population might be warranted., Competing Interests: Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
10. Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021.
- Author
-
Mateo-Urdiales A, Spila Alegiani S, Fabiani M, Pezzotti P, Filia A, Massari M, Riccardo F, Tallon M, Proietti V, Del Manso M, Puopolo M, Spuri M, Morciano C, D'Ancona FP, Da Cas R, Battilomo S, Bella A, and Menniti-Ippolito F
- Subjects
- COVID-19 Vaccines, Hospitalization, Hospitals, Humans, Italy epidemiology, SARS-CoV-2, COVID-19, Vaccines
- Abstract
To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0-14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21-0.24) 43-49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09-0.15) and 93% (IRR: 0.07; 95% CI: 0.04-0.11) reductions 36-42 days post-first dose. Our results support ongoing vaccination campaigns.
- Published
- 2021
- Full Text
- View/download PDF
11. Consensus paper on postural dysfunction: recommendations for prevention, diagnosis and therapy.
- Author
-
Saggini R, Anastasi GP, Battilomo S, Maietta Latessa P, Costanzo G, Di Carlo F, Festa F, Giardinelli G, Macrì F, Mastropasqua L, Nardone M, Nicoletti G, Orsini A, Pastorelli M, Pellegrino R, Trevisan M, La Mesa L, Le Pera AM, Privitera MG, Ralli G, Villani C, Bricot B, Davidson RG, Hassdenteufel A, Hawamdeh ZM, Kleinrensink GJ, Matheron E, Stoev VL, Stratulat S, Tiron S, Villeneuve P, Paolucci T, and Bellomo RG
- Subjects
- Consensus, Foot, Postural Balance, Posture
- Abstract
Good fundamentals of posture and balance are essential for the efficient performance of both simple daily tasks and more complex movement patterns. In particular, postural balance is the ability to keep the body in equilibrium and to regain balance after the shift of body segments: postural control mechanisms of integration of the visual, vestibular and foot afferential channels contribute to this. This document provides recommendations based on scientific evidence, clinical practice, and consensus between experts concerning the prevention, diagnosis, and treatment of postural dysfunction at the three stages of life as the developmental age, adult age, and old age > 65 years and follows the "National Guidelines on Classification and Measuring of Posture and its Dysfunctions" per the Italian Ministry of Health (December 2017). The paper answers four main questions: i) "Which measures can be adopted to prevent postural dysfunctions?" ii) "What can we do in order to make a correct diagnosis of postural dysfunction?" iii) "What are the correct treatment programs for postural dysfunctions?" iv) Which professional competencies and experiences are useful for preventing, diagnosing and treating postural dysfunctions? By the Consensus of the Experts and the scientific evidence, emerge that the approach to postural dysfunctions requires a multidisciplinary and interdisciplinary team. Furthermore, rehabilitation treatment interventions must be specific to the age groups that have been indicated, to consider the integration of the main systems and subsystems of postural control that change with age., (Copyright 2020 Biolife Sas. www.biolifesas.org.)
- Published
- 2021
- Full Text
- View/download PDF
12. [Analysis of the activities of the network of the Family Care Centres to relaunch their role: main results of the 2017 CCM Project].
- Author
-
Lauria L, Bortolus R, Battilomo S, Lega I, Pizzi E, Tamburini C, and Donati S
- Subjects
- Female, Humans, Italy, Surveys and Questionnaires
- Abstract
Introduction: in 2017, the Italian Ministry of Health funded the project "Analysis of the activities of the network of the Family Care Centers (FCCs) to relaunch their role" aimed at updating the state of the art of the national FCCs. The project was coordinated by the Italian National Institute of Health (INIH). The present paper focuses on a selection of the project's results., Objectives: to describe some characteristics of the regional and Local Health Unit governance of the FCCs, and the care offered by the FCCs in different fields of activity., Design: online census survey on three organizational levels of the FCCs: regional governance, coordination at the Local Health Unit level, and at the single FCC level. Data were collected through dedicated web forms via a national network of reference professionals., Setting and Participants: all the Italian Regions and Autonomous Provinces, 207 Local Health Unit coordinators, and 1,859 FCC's professionals were involved. Nineteen Regions (response rate: 100%), 183 coordinators (response rate: 88.4%), and 1,557 FCCs professionals (response rate: 83.7%) participated in the survey., Results: the project found a lack of FCCs and of FCCs health professionals throughout the country compared to the national reference standards for these services, and a great interregional variability in the FCCs governance. Women's health according to a life-course approach is the centre of the FCCs activities, although assistance modalities differ by geographic area., Conclusions: to relaunch the FCCs role, it is urgent to strengthen their network throughout the country, their multidisciplinary teams, and their integration with other social and health services.
- Published
- 2021
- Full Text
- View/download PDF
13. A blended training programme for healthcare professionals aimed at strengthening territorial networks for the prevention and contrast of gender-based violence.
- Author
-
Colucci A, Luzi AM, Fanales Belasio E, Barbina D, Mazzaccara A, Farchi S, and Battilomo S
- Subjects
- Adult, Attitude of Health Personnel, Diagnosis, Diagnosis-Related Groups, Female, Health Personnel psychology, Humans, Interdisciplinary Communication, Male, Middle Aged, Professional Competence, Program Evaluation, Education, Distance organization & administration, Emergency Service, Hospital, Gender-Based Violence prevention & control, Health Personnel education
- Abstract
Objectives: a blended training programme combining residential meetings (de visu) and distance training course (DTC) have been developed in order to provide the key elements for prevention, individuation, and care of women victims of violence., Design: the Project involved the identification and testing of a systematic methodology of blended training addressed to social and health operators of 28 Emergency Room (ER) Units in 4 Italian regions (Lombardy - Northern Italy, Lazio - Central Italy, Campania and Sicily - Southern Italy). Tuscany region (Central Italy) collaborated through experts in the field from the Grosseto Task Force. This training approach specifically aimed to increase the professional competences for diagnosis, management and treatment of gender-based violence, as well as to strengthen multidisciplinary territorial networks against violence., Setting and Participants: in this Project, 28 ERs in the four Italian regions mentioned above were selected because of their involvement in managing gender-based violence. This selection was performed by a coordinator, one for each region, who also coordinated the recruitment of personnel to be involved in the training programme. The programme has therefore been proposed to social and health operators and police officers in the ERs recruited. In each ER, two referents were identified (a doctor and a nurse) in order to ensure a constant connection between the course participants and the experts involved in the management of the Project and the DTC platform., Main Outcome Measures: evaluation of the increase of knowledge relatively to gender-based violence issue in the ER professionals who have concluded the blended training programme. A systematic analysis and comparison of all accesses concerning women aged ≥14 years in the period 1 July-31 December 2014 (before the blended training programme) and in the period 1 July-31 December 2016 (after the blended training program)., Results: among the 866 registered professionals, 636 participants (73.5%) completed the course, 202 (23.3%) professionals did not complete it, 21 (2.4%) did not pass the certification test, and 7 (0.8%) participated as Auditors. Among the participants who completed the course, most of them (70.8%) were females; the average age was 45 for both males and females. The most represented professional role was the nurse (61%), followed by the medical doctor (27.2%). Based on our data, in the post-training period, an increased number of cases of violence were correctly recorded in comparison to the pre-training period., Conclusion: the Project allowed to define a training strategy for health professionals of the ERs who respond daily to the health needs of women who are victims of violence. The blended training programme combining residential meetings (de visu) and distance training course has been developed in order to provide the key elements for prevention, individuation, and care of women victims of violence. The observed improvement in the recording and management of cases of gender-based violence is probably due to a greater competence in the awareness and use of specific diagnostic codes by ER professionals.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.